UW Zhang Lab

UW Pathology Home Labs
Lab Members
Director's Message
Research Interests

Related Info
Contact Us
  Zhang Lab Publications


Please Click on "*" for article links (PubMed)

* Matsumoto J, Stewart T, Sheng L, Li N, Bullock C, Song N, Shi M, Banks ES, and Transmission of α -synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease? Acta Neuropathologica Communications. Sept (2017).

* Pottiez G, Yang L, Stewart T, Song N, Aro P, Galasko DR, Quinn JF, Peskind ER, Shi M, and Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1–42 in CSF for the Diagnosis of Alzheimer’s Disease. Journal of proteome research 16 (3), 1228-1238, (2017)

* Matsumoto J, Stewart T, Banks WA, and The transport mechanism of extracellular vesicles at the blood-brain barrier. Current pharmaceutical design. Sept (2017)

* Banks WA, Kovac A, Majerova P, Bullock KM, Shi M, and Tau Proteins Cross the Blood-Brain Barrier. Journal of Alzheimer's Disease 55 (1), 411-419, (2017)

* Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Montine TJ, Banks WA, and . CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. Alzheimers Dement. (2016)

* Atik A, Stewart T, and . Alpha-Synuclein as a Biomarker for Parkinson's Disease. Brain Pathol. (2016)

* Wang S, Chu CH, Guo M, Jiang L, Nie H, Zhang W, Wilson B, Yang L, Stewart T, Hong JS, and . Identification of a specific α-synuclein peptide (α-Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons. J Neuroinflammation. (2016)

* Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M1, and . Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease. J Alzheimers Dis. (2015)

* Wang S, Chu CH, Stewart T, Ginghina C, Wang Y, Nie H, Guo M, Wilson B, Hong JS, and . α-Synuclein, a chemoattractant, directs microglial migration via H2 O2 -dependent Lyn phosphorylation. Proc Natl Acad Sci U S A. (2015)

* Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; Parkinson Study Group DATATOP Investigators, and . CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat Disord. (2015)

* Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, . Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun. (2015)

* Lin X, Shi M, Masilamoni JG, Dator R, Movius J, Aro P, Smith Y, . Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. Biochim Biophys Acta. (2015)

* Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, Lin X, Bammler TK, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, . Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics. 2015 Mar;14(3):544-55. doi: 10.1074/mcp.M114.040576. Epub (2015)

* Stewart T, Sui YT, Gonzalez-Cuyar LF, Wong DT, Akin DM, Tumas V, Aasly J, Ashmore E, Aro P, Ginghina C, Korff A, Zabetian CP, Leverenz JB, Shi M, (2014). Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiol Aging. 35(2):418-20. Feb (2014).

* Mattsson N, Insel P, Tosun D, , Jack CR Jr, Galasko D, Weiner M; Alzheimer's Disease Neuroimaging Initiative (2013). Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. PLoS One. 8(12):e85443. Dec (2013).

* Gonzalez-Cuyar LF, Nelson G, Criswell SR, Ho P, Lonzanida JA, Checkoway H, Seixas N, Gelman BB, Evanoff BA, Murray J, , Racette BA (2013). Quantitative neuropathology associated with chronic manganese exposure in South African mine workers. Neurotoxicology. pii:S0161-813X(13)00189-7. Dec (2013).

* , Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ; Parkinson Study Group DATATOP Investigators, Cain KC, Shi M (2013). Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol. 126(5):671-82. Nov (2013).

* Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, , Lampe J, Craft S (2013). Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 70(8):972-80. Aug (2013).

* Mattison HA1, Nie H, Gao H, Zhou H, Hong JS, (2013). Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice. J Neuroimmunol. 257(1-2):110-5. Apr (2013).

* Shi M, Hwang H, (2013). Quantitative characterization of glycoproteins in neurodegenerative disorders using iTRAQ. Methods Mol Biol. 951:279-96. (2013).

* Wang J, Hoekstra JG, Zuo C, Cook TJ, (2013). Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discov Today. 18(3-4):155-62. Feb (2013).

* Korff A1, Liu C, Ginghina C, Shi M, ; Alzheimer's Disease Neuroimaging Initiative (2013). α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis. 36(4):679-88. Jan (2013).

* Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M, (2012). DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep. 2:954. (2012).

* Haas BR1, Stewart TH, (2012). Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener. 1(1):11. May (2012).

* Mattison HA, Stewart T, (2012). Applying bioinformatics to proteomics: is machine learning the answer to biomarker discovery for PD and MSA? Mov Disord. 27(13): 1595-7. Nov (2012).

* Racette BA, Criswell SR, Lundin JI, Hobson A, Seixas N, Kotzbauer PT, Evanoff BA, Perlmutter JS, , Sheppard L, Checkoway H.(2012). Increased risk of parkinsonism associated with welding exposure. Neurotoxicology. 33(5):1356-61. Oct (2012).

* Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, and (2012). Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med. Feb (2012).

* Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, Wang Y, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, and (2012). DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging. (2012).

* Shi M, and (2011). CSF α-synuclein, tau, and amyloid β in Parkinson's disease. Lancet Neurol. Aug;10; (2011).

* Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, and (2011). Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. Apr (2011).

* Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, and (2011). Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. Mar (2011).

* Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, and(2011). Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain. Jul (2011).

* Montine, T. Shi, M, .and (2010). CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 15;25(15): 2682-5. Nov (2010).

* Mata, I, and Zabeitian C (2010). A SNCA Variant Associated with Parkinson's Disease and Plasma α-Synuclein Level. Arch Neurol. (2010).

* Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, and (2010). Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 480:78-82, (2010).

* Liu J, Shi M, Hong Z, Zhang J, Bradner J, Quinn T, Beyer RP, Mcgeer PL, Chen S, and (2010). Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxicity induced by alpha-synuclein. Proteomics. 10(11):2138-50, (2010).

* Rostomily RC, Born DE, Beyer RP, Jin J, Alvord EC Jr, Mikheev AM, Matthews RT, Pan C, Khorasani L, Sonnen JA, Montine TJ, Shi M, and (2010). Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. J Proteome Res. 7;9(5):2610-8, (2010).

* Caudle WM, Bammler TK, Lin Y, Pan S, and (2010). Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother, 10(6):925-42, (2010).

* Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, and (2010). DJ-1 and synuclein as biomarkers of Parkinson's disease. Brain, 133:713-26, (2010).

* Oh JH, Pan S, , Gao J (2010). MSQ: A tool for quantification of proteomics data generated by LC-MALDI TOF/TOF based targeted quantitative proteomics platform. Rapid Comm Mass Spec, 24(4):403-8, (2010).

* Hwang H, Zhang JP, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, Montine TJ, Pan S, Nutt J, Albin R, Gearing M, Beyer RP, Shi M, and (2010). Glycoproteomics in Neurodegenerative Diseases. Mass Spec Reviews, 29(1):79-125, (2010).

* Caudle WM, (2009). Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol. 220:230-3, (2009).

* Shi M, Bradner J, Bammler TK, Eaton DL, Zhang JP, Ye ZC, Wilson AM, Montine TJ, Pan C and (2009). Identification of synaptosomal glutathione S-transferase Pi as a key protein in Parkinson disease progression. Am J Pathol. Jun, 4; (2009).

* Caudle WM, Kitsou E, Li J, Bradner J, (2009). A role for a novel protein, nucleolin, in Parkinson's disease, Neurosci Lett. (2009) Jul 31;459(1):11-5. Epub May, 4; (2009).

* Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, Chen S, (2009). Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci. 4;29(5):1480-5.(2009).

* Pan S, Aebersold R, Chen R, Rush J, Goodlett DR, McIntosh MW, , Brentnall TA (2009). Mass spectrometry based targeted protein quantification: methods and applications, J. Proteome Res. 6;8(2):787-797. (2009).

* Shi M, Caudle WM and (2008). Biomarker Discovery in Neurodegenerative Diseases: A Proteomic Approach, Neurobiol Dis. Sep 26, (2008) online.

* Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, Liu Y, Qian L, Wilson B, Di Monte DA, Ali SF, , Block ML, Hong JS (2008). Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease, J Immunol. 181(10):7194-204.(2008).

* Kitsou E, Pan S, Zhang JP, Dickson DW, Albin R, Gearing M, Kashima DT, Wang Y, Beyer DP, Zhou Y, Pan C, Caudle WM, (2008), Identification of proteins in human substantia nigra. Proteomics, Clin Application, 2 (5):776-782. (2008).

* Liu J, Hong Z, Ding JQ, Liu JR, , Chen SD (2008), Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies. J Proteome Res. 7(5):2033-49. (2008).

* Caudle WM, Pan S, Shi M, Quinn T, Hoekstra J, Beyer RP, Montine TJ, (2008). Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. Proteomics - Clin Application 2(10-11): 1484-1497. (2008).

* , Keene CD, Pan C, Montine KS, Montine TJ (2008). Proteomics of human neurodegenerative diseases. J Neuropathol Exp Neurol. 67(10):923-32. (2008).

* Klegeris A, Li J, Bammler TK, Jin J, Zhu D, Kashima DT, Pan S, Hashioka S, Maguire J, McGeer PL, (2008). Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP-1 cell neurotoxicity. Glia. 56(6):675-85. (2008).

* Shi M, Jin J, Wang Y, Beyer RP, Kitsou E, Albin RL, Gearing M, Pan C, (2008). Mortalin: A Protein Associated With Progression of Parkinson Disease? 1: J Neuropathol Exp Neurol. 67(2):117-124. (2008).

* , Sokal I, Peskind E, Quinn J, Jankovic J, Kenney C, Chung K, Millard S, Nutt J, Montine TJ (2008). CSF multianalyte profile distinguishes Alzheimer's and Parkinson's diseases, Am J Clin Path, 129(4):526-9. (2008).

* Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Oh JH, Gao J, Zhang J, Montine T, (2008). Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. J Proteome Res. 7(2):720-30. (2008).

* Pan S, Shi M, Jin J, Albin RL, Lieberman A, Gearing M, Lin B, Pan C, Yan X, Kashima DT, (2008). Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. Mol Cell Proteomics. 6 (10):1818-23. (2008).

* (2007). Proteomics of Human cerebrospinal fluid : the good, the bad, and the ugly. Proteomics Clinical Applications. Rev. 2007,1, 805-919. (2007).

* Liu, J, Zhou Y, Liu J, Fong H, Murray TM, and, (2007). Identification of proteins involved in microglial endocytosis of alpha-synuclein. J Proteome Res. 6(9):3614-27 (2007).

* Yang W, Woltjer RL, Sokal I, Pan C, Wang Y, Brodey M, Peskind ER, Leverenz JB, , Perl DP, Galasko DR, Montine TJ (2007). Quantitative Proteomics Identifies Surfactant-Resistant alpha-Synuclein in Cerebral Cortex of Parkinsonism-Dementia Complex of Guam but Not Alzheimer's Disease or Progressive Supranuclear Palsy. Am J Pathol. 171(3):993-1002. (2007).

* Jin J, Davis J, Zhu D, Kashima DT, Leroureil M, Pan, C, Montine KS, and (2007). Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells, BMC Neurology, 8:67. Aug (2007).

* Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, , Peskind ER, and Montine TJ (2007). CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007 69(7):631-9. (2007).

* Sonnen JA, Keene CD, Montine KS, Li G, Peskind ER, , Montine TJ (2007). Biomarkers for Alzheimer's disease, Expert Rev Neurother. 7(8):1021-8. (2007).

* Chen L, Davis J, Jin J, Zhou Y, Wang Y, Liu J, Lockhart P, and (2007). Oligomeric alpha-synuclein inhibits tubulin polymerization, Biochem. Biophy. Res. Comm, 356(3):548-53. (2007).

* Zhang W, Dallas S, Guo JP, Pang H, Wilson B, Miller DS, Jia J, Chen B, Zhang W, McGeer PL, Hong JS, and (2007). Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein, Glia, 55:1178-88. (2007).

* Jin J, Li GJ, Davis J, Zhu D, Wang C, Pan C, and (2007). Identification of novel proteins associated with both alpha-synuclein and DJ-1., Mol Cell Proteomics. 6:845-59. (2007).

* Jin J, Shie FS, Liu J, Wang Y, Davis J, Schantz AM, Montine KS, Montine TJ, (2007). Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein, J Neuroinflammation. 4;4:2. (2007).

* Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, Lin B, Goodlett DR, Taylor G, Eng J, (2007). A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectroscopy. Proteomics, 7(3):469-73. (2007).

* Leverenz, JB, Umar I, Wang Q, Montine TJ, Jin J, Pan C, Shin J, Zhu D, and (2007). Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol., 17(2):139-145. (2007).

* and Montine TJ (2007). Proteomic discovery of CSF biomarkers for Alzheimer's disease. Ann Neurol. 61(5):497, (2007).

* Pan S, Wang W, Quinn JF, Peskind ER, Waichunas D, Wimberger JT, Jin J, Li DJ, Zhu D, Pan C, and (2006). Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach, Journal of Proteomic Research, 5:2769-2779. (2006).

* Zhang H, Loriaux P, Eng J, Campbell D, Keller A, Moss P, Bonneau R, Zhang N, Zhou Y, Wollscheid B, Cooke K, Yi EC, Lee H, Peskind ER, , Smith RD, Aebersold R (2006). UniPep, a database for human N-linked glycosites: A Resource for Biomarker Discovery, Genome Biology, August online. (2006).

* Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li J, Liu Y, Waichunas D, Montine TJ, (2006). Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders, Journal of Alzheimer's Disease 9:293-348. (2006).

* Jin J, Hulette C, Wang Y, Zhang T, Pan C, Wadhwa R, and and, (2006). Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics, 5(7):1193-204. Epub Mar 24; (2006).

* McLaughlin P, Zhou Y, Ma T, Liu J, Kovacs M, and, (2006). Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 53:567-82. (2006).

* Xu J, Chen J, Peskind, ER, Jin J, Eng J, Pan P, Montine TJ, Goodlett DR, (2006). Characterization of proteome of human cerebral spinal fluid. Int. Rev Neurob, 73:29-98. (2006).

* Thakker MM, , Sires BS (2005). Chronic Inflammation from polycarbonate motility peg inhibits osteogenesis in a human hydroxyapatite orbital implant. Ophthal Plast Reconstr Surg. 21(5):399-401. (2005).

* Xiong X, Shie FS, , Lee CP, and Ho YS (2005). Prevention of mitochondrial dysfunction in post-traumatic mouse brain by superoxide dismutase. J. Neurochem. 95(3):732-44. (2005).

* Woltjer RL, Cimino PJ, Boutt, AM, Schantz AM, Montine KS, Larson EB, Bird T, Quinn JF, , Montine TJ (2005). Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. FASEB J. 19(13):1923-5. Nov (2005).

* Zhou Y, Wang Y, Kovacs M, Jin J, and (2005). Microglial activation induced by neurodegeneration : A proteomic analysis. Molecular Cellular Proteomics, Oct;4(10):1471-9. (2005).

* , Goodlett DR, Peskind ER, Quinn, JF, Zhou, Y, Pan, P, Yi, E, Eng, J, Aebersold, R. and Montine, TJ (2005). Quantitative proteomics of cerebrospinal fluid from Alzheimer disease and controls using isotope-coded affinity tags. Journal of Alzheimer's Disease, 7:125-33. (2005).

* Yenerel, NM, Boada, R, Clifton, B, , and Saperstein, DA (2005). Ganciclovir Implant with Cyst-like Abnormality. Arch Ophthal, 123(2):282-3. (2005).

* Wang Q, Woltjer RL, Cimino PJ, Pan C, Montine KS, , Montine TJ (2005). Proteomic analysis of neurofibrillary tangles in Alzheimer Disease identifies GAPDH as a detergent-insoluble paired helical filament tau-binding protein. FASEB J. 19:869-71. (2005).

* Jin J, Meredith G, Chen L, Zhou Y, Xu J, Xie FX, Lockhart P, and (2005). Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Molecular Brain Res, 24;134(1):119-38. (2005).

* Zhang W, Wang T, Pei Z, Meng Y, Wu XF, Belinda W, Zhang W, Hong JS and (2005). Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:532-541. (2005).

* Zaja-Milatovic S, Schantz, A, , Montine KS, Samii A, Deutch A, and Montine, TJ (2005), Dendritic Degeneration in Neostriatal Medium Spiny Neurons in Parkinson Disease. Neurol 64:545-7.

* , Goodlett, DR, Peskind, ER, Quinn, JF, Zhou, Y, Pan, P, Yi, E, Eng, J, Aebersold, R. and Montine, TJ (2005), Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging, 26: 207-227. (2005).

* Xiong Y, Shie FS, , Lee CP, Ho YS (2004). The protective role of cellular glutathione peroxidase against mitochondrial dysfunction in head trauma, J Stroke and Cereb Dis, 13:129-137. (2004).

* Zhou Y, Gu G, Goodlett, DR, Yi, EC, Eng J, Pan P, Montine, KS, Montine, TJ, Aebersold, RH, and (2004). Analysis of alpha-Synuclein Associated Proteins by Quantitative Proteomics. J. Biol. Chem, 279:39155-39164. (2004).

* Zhou Y, Shie FS, Piccardo P, Montine TJ and (2004). Proteasomal inhibition induced by manganese ethylene-bis-dithiocarbamate: relevance to Parkinson's disease. Neuroscience, 128:281-291. (2004).

* , and Goodlett, DR (2004). Proteomic approach to studying Parkinson's disease. Mol Neurol, 29:271-88. (2004).

* Fessel JP, Hulette C, Powell S, Roberts LJ, and (2003). Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem. 85:645-50. (2003).

* , Fitsanakis VA, Gu G, Jing DJ, Ao M, Amarnath V, and Montine TJ (2003) Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: A link through mitochondrial dysfunction. J. Neurochem. 84:1-11. (2003).

* Fitsanakis VA, Amarnath V, Moore JT, , and Montine TJ (2002). Catalysis of catechol oxidation by metal-dithiocarbamate complexes in pesticides. Free Rad Biol Med 33(12):1714-23. (2002).

* Sidell KR, , and Montine TJ (2002). Dopamine thioethers: formation in brain and neurotoxicity Neurotoxicity Res. 4: 663-669. (2002).

N/A (2002). Diagnosis of parkinsonism at autopsy Ann. Contem. Diag. Path. 5:45-50. (2002).

* Gu G, Patricio FR, Golden GT, Woltjer R, Hulette C, Montine TJ, and (2002). Mitochondrial DNA Deletions/Rearrangements in Parkinson's Disease and Related Neurodegenerative Disorders J. Neuropathol. Exp. Neurol 61:634-9. (2002).

* Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, , Montine T, Sayre LM, Smith MA (2002) Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett. 8;319(1):25-8.(2002).

* , Montine TJ, Smith MA, Siedlak SL, Robertson D, and Perry G (2002). The mitochondrial common deletion in Parkinson's disease and related movement disorders. Parkinsonism and Related Dis 8:165-170. (2002).

* Boyd A. and (2001). Hemangioblastoma arising from the skin. Am J Dermatopathol 23: 482-4. (2001).

* Tsai JS, Sivak-Callcott JA, Haik BG, , McLean IW (2001). Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J Glaucoma 10:411-3. (2001).

* Shappell SB, Keeney DS, , Page R, Olson SJ, and Brash AR (2001). 15-Lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. J Invest Dermatol (2001) Jul;117(1):36-43.

* Amarnath V, Amarnath K, Graham DG, Qi Q, Valentine H, , and Valentine WM (2001). Identification of a new urinary metabolite of carbon disulfide using an improved method for determination of 2-thioxothiazolidine-4-carboxyulic acid. Chem. Res. Toxical 14:1277-1283. (2001).

* Montine TJ, Amarnath V, Picklo MJ, Sidell KR, , Graham DG (2000). Dopamine mercapturate can augment dopaminergic neurodegeneration. Drug Metab Rev 32(3-4):363-76. (2000).

* , Kravtsov V, Amarnath V, Picklo MJ, Graham DG, and Montine TJ (2000). Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: Relevance to Parkinson's disease. J. Neurochem. 74:970-978. (2000).

* , Graham DG, Montine TJ, and Ho YS (2000). Enhanced N-methyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in Cu-Zn superoxide dismutase or glutathione peroxidase J. Neuropathol. Exp. Neurol 59:58-66. (2000).

* , Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, and Montine TJ (1999). Parkinson's disease is associated with oxidative damage to cytoplamic DNA and RNA. Am. J. Pathol. 154: 1423-1430. (1999).

N/A Nunomura A, Perry G, , Montine TJ, Takeda A, Chiba S, and Smith MA (1999). RNA oxidation in Alzheimer and Parkinson disease. J. Anti-Aging Med. 2:227-230. (1999).

* Picklo MJ, , Nguyen VQ, Graham DG, and Montine TJ (1999). High-pressure liquid chromatography quantification of cytochrome C using 393 nm detection. Analytic Biochem. 276:166-170. (1999).

* , Price J, Graham DG, and Montine TJ (1998). Secondary excitotoxicity contributes to dopamine induced apoptosis in dopaminergic neuronal cultures. Biochem. Biophy. Res. Comm. 248:812-816. (1998).

* Piantadosi CA, , Folz R, Levin ED, and Schmechel D (1997). Apoptosis and delayed neuronal death after carbon monoxide poisoning in the rat. Exp. Neurol.. 147:103-114. (1997).

* Piantadosi CA, , and Demchenko IT (1997). Production of hydroxyl radicals in the hipocampus after CO hypoxia or hypoxic hypoxia in the rat. J. Free Radic. Biol. Med. 22:725-732. (1997).

* Piantadosi CA, and (1996). Mitochondrial origin of reactive oxygen species after brain ischemia in vivo. Stroke 27:327-332. (1996).

* Kil HY, , and Piantadosi CA (1996). Ischemic brain temperature alters hydroxyl radical production in rats during cerebral ischemia/reperfusion. J. Cereb. Blood Flow Metab. 16:100-106. (1996).

* , Sam AD, Klitzman B and Piantadosi CA (1995). Inhibition of nitric oxide synthase does not decrease oxygenation in brain cortex of rats exposed to hyperbaric oxygen. Undersea Hyper. Med. 22:377-382. (1995).

* , Benveniste H, Klitzman BM and Piantadosi CA (1995). Nitric oxide synthase inhibition alters extracellular glutamate concentration after global cerebral ischemia. Stroke 26:298-304. (1995).

* Piantadosi CA, Tatro L and (1995). Hydroxyl radical production in the brain after CO hypoxia in rats. J. Free Radic. Biol. Med. 18:603-609. (1995).

* , and Piantadosi CA (1994). Production of hydroxyl radicals in rat hippocampus during global brain ischemia/reperfusion. Neurosci. Lett. 177:127-130. (1994).

* , Benveniste H and Piantadosi CA (1993). Inhibition of nitric oxide synthase increases extracellular cerebral glutamate concentration after global ischemia. Neurosci. Lett. 157:179-182. (1993).

* , Su YF, Oury TD and Piantadosi CA (1993). Cerebral amino acids, norepinephrine and nitric oxide metabolism in CNS oxygen toxicity. Brain Res. 606:56-62. (1993).

* Simonson SG, , Canada AT, Su YF, Benveniste H and Piantadosi CA (1993). Hydrogen peroxide production by monoamine oxidase during ischemia-reperfusion in the rat brain. J. Cereb. Blood Flow Metab. 13:125-134. (1993).

* , and Piantadosi CA (1992). Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J. Clin. Invest. 90:1193-1199. (1992).

* Ghio AJ, , and Piantadosi CA (1992). Generation of hydroxyl radical by crocidolite asbestos is proportional to surface [Fe3+]. Arch. Biochem. Biophys. 298:646-650. (1992).

* , and Piantadosi CA (1991). Prevention of H2O2 generation by monoamine oxidase protects against CNS O2 toxicity. J. Appl. Physiol. 71:1057-1061. (1991).

* , Fife CE, Currie MS, Moon RE, Piantadosi CA and Vann RD (1991). Venous gas emboli and complement activation after deep repetitive air diving. Undersea Biomed. Res. 18:293-302. (1991).

N/A , and Ni GT (1989). Prevention of decompression sickness with drugs. J. Env. Med. of China 26:354-359. (1989).

N/A (1988). Metabolites of arachidonic acid and decompression sickness. Med. Foreign Countries, 5:270-274. (1988).

* , and Ni GT (1986). Changes in thromboxane A2 and prostacyclin in rabbits suffering from decompression sickness. Acad. 2nd Milit. Med. Univ. 7:762-764. (1986).

Book Chapters

and Montine TJ. Oxidative Processes. Primer on the Autonomic Neurvous System, 2nd Edition, ed. D. Robertson. In press.

Graham DG, Picklo MJ, Amarnath V, , and Montine TJ (2001). Role of quinones in catechol neurotoxicity. In press. (2001).

Montine TJ, Amarnath V, , and. Graham GG (2001). Role of catechol thioethers in neurotoxicity. Ed C.R. Creveling. In press. (2001).

, Oury TD, Tatro LG and Piantadosi CA. (1994) Cerebral amino acids and hyperbaric oxygen toxicity. In: Bennett P.B. and R.E. Marquis ed. Basic and Applied High Pressure Biology, University of Rochester Press, New York, pp 431-436. (1994).